EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy

Xu-Jie Zhou

MedComm · 2025-09 · 6 (9)

DOI: 10.1002/mco2.70382 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 08.09.2025. Verfasst von Xu-Jie Zhou. Beteiligte Einrichtung: Renal Division Kidney Genetics Center Key Laboratory of Renal Disease National Health Commission Peking University First Hospital Peking University I…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 354 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Academy of Medical Sciences, Medical School, University of Michigan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunoglobulin A nephropathy (IgAN), the most prevalent primary glomerulonephritis globally, is characterized by mesangial IgA deposition and heterogeneous clinical trajectories. Historically, management relied on renin–angiotensin system inhibition and empirical immunosuppression, yet high lifetime kidney failure risk persists despite optimized care. This review synthesizes advances in molecular pathogenesis, highlighting how the traditional multi‐hit hypothesis—while foundational for targeted therapy development—fails to capture IgAN's recurrent, self‐amplifying nature. We introduce the “spiral hypothesis” as a dynamic model of cyclical immune‐injury cascades, better explaining disease chronicity and necessitating sustained maintenance therapy. Emerging targeted therapies—including B‐cell targeted agents (e.g., APRIL/BAFF inhibitors), complement inhibitors (e.g., iptacopan), and mucosal immunomodulators (e.g., TRF‐budesonide)—enable early intervention addressing both upstream immunological drivers and downstream fibrotic pathways. We critically evaluate treat‐to‐target frameworks, defining remission endpoints (proteinuria

Schlagwörter

Stichwörter der Autor:innen

B lymphocyteIgA nephropathyclinical trialscomplementmolecular pathogenesistargeted therapy

Autor:innen und Institutionen

  • Renal Division Kidney Genetics Center Key Laboratory of Renal Disease National Health Commission Peking University First Hospital Peking University Institute of Nephrology Peking University Institute of Nephrology Key L…

Förderung

  • National Natural Science Foundation of China
  • Chinese Academy of Medical Sciences
  • Medical School, University of Michigan
  • National Key Research and Development Program of China

Zitieren

APA

Zhou, X. J. (2025). Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy. MedComm, 6(9). https://doi.org/10.1002/mco2.70382

Vancouver

Zhou XJ. Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy. MedComm. 2025;6(9). doi:10.1002/mco2.70382

BibTeX
@article{Zhou2025,
  author = {Zhou, Xu-Jie},
  title = {Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {9},
  doi = {10.1002/mco2.70382}
}
Kostenlos starten →